Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies

Biologicals

Volumn 26, Issue 1, 1998, Pages 7-15

  Lang, J ^a   Gravenstein, S ^b   Briggs, D ^c   Miller, B ^b   Froeschle, J ^d   Dukes, C ^d   Le Mener, V ^a   Lutsch, C ^a  

^a Pasteur Merieux Connaught Intl   (France)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c KANSAS STATE UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032029358     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0117     Document Type: Article

References (26)

1. 1. WHO. Fighting disease and fostering development. WHO Health Report 1996. p. 24.
2. 2. Nicholson KG. Modern Vaccines: Rabies. Lancet 1990; 330: 1201-1205.
3. 3. World Health Organization Expert Committee on Rabies. Eighth Report. WHO Tech. Rep. Ser. 1992.
4. 4. CDC. Recommendations of the immunization practices advisory committee. Rabies prevention - United States 1991. MMWR 1991; 40(RR-3): 1-19.
5. 5. Balthazard M, Bahmanyar M. Essai pratique du sérum antirabique chez les mordus par loups enragés. Bull Org Mond Santé 1955; 13: 747-772.
6. 6. Fangtao L, Shubeng C, Yinzhon W et al. Use of serum and vaccine in combination for prophylaxis following exposure to rabies. Rev Inf Dis 1988; 10(Suppl. 14): 766-770.
7. 7. Wilde H, Chomchey P, Punyaratabandhu P et al. Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull WHO 1989; 67: 731-736.
8. 8. Miranda ME, Quiambao B, Santa Ana J et al. A new generation of purified, heat-treated equine rabies immune globulins. Results of a comparative, sham post-exposure prophylaxis trial using Vero-cell rabies vaccine. VII Annual International Meeting on Research Advances & Rabies Control in the Americas, December 1996, Atlanta. p. 100 (Abstract).
9. 9. Wells MA, Willer AE, Epstein JS et al. Inactivation and partition of human T-cell lymphotropic virus type III during ethanol fractionation of plasma. Transfusion 1986; 26: 210-213.
10. 10. Helmick C, Johnstone C, Sumner J, Winkler W, Fager S. A clinical study of Merieux human rabies immune globulin. J Biol Stand 1982; 10: 357-367.
11. 11. Smith JS, Yager PA, Baer GM. A rapid tissue culture test for determining rabies neutralizing antibodies. WHO Monograph Series 1973; 23: 354-357.
12. 12. European Pharmacopoeia. Human Normal Immunoglobulin. 1997; 0338: 1013-1015.
13. 13. European Pharmacopoeia. Anticomplementary activity testing of immunoglobulins 1997; 2.6.17: 98-101.
14. 14. Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis 1988; 18: 229-233.
15. 15. Wilde H, Glueck R, Khawplod P et al. Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients. Vaccine 1995; 13: 593-596.
16. 16. Mertz GJ, Nelson KE, Vithayasai V et al. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin. J Inf Dis 1982; 145: 720-727.
17. 17. Khawplod P, Glueck R, Wilde H, Tantawichien T, Chomchey P, Thipkong P, Benjavongkulchai M, Sitprija V. Immunogenicity of purified duck embryo rabies vaccine (Lyssavac-N) with use of the WHO-approved intradermal postexposure regimen. Clin Infect Dis 1995; 20: 645-651.
18. 18. Nicholson KG, Turner GS. Studies with human diploid cell strain rabies vaccine and human antirabies immunoglobulin in man. Dev Biol Stand 1978; 40: 115-120.
19. 19. Berlin BS. Rabies. New Eng J Med 1994; 330: 1088-1089.
20. 20. Dean DJ, Baer GM, Thompson WR. Studies on the local treatment of rabies-infected wounds. Bull. WHO 1963; 28: 477-486.
21. 21. Cabasso VJ. Local wound treatment and passive immunization. In: Baer GM (ed.) The Natural History of Rabies. CRC Press, Boston, 1991; 551-570.
22. 22. Wilde H, Sirikawin S, Sabcharoen A et al. Failure of postexposure treatment of rabies in children. Clin Inf Dis 1996; 22: 228-232.
23. 23. Wilde H, Choomkasien P, Hemachudha T et al. Failure of rabies postexposure treatment in Thailand. Vaccine 1989; 7: 49-51.
24. 24. Loofbourow J, Cabasso V, Roby R et al. Human rabies immune globulin. Clinical trials and dose determination. JAMA 1973; 224: 871-874.
25. 25. Cabasso VJ, Loofbourow JC, Roby RE et al. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull WHO 1971; 45: 303-315.
26. 26. Kuwert EK, Werner J, Marcus I et al. Serovaccination by human immune globulin and HDCS-vaccine against rabies. Dev Biol Stand 1978; 40: 129-136.